Open Access

The prM-independent packaging of pseudotyped Japanese encephalitis virus

  • Hee Jung Lee1,
  • Kyung-Il Min2,
  • Jungeun Lee1,
  • Sin-Hyung Kang1,
  • Wonkyung Jeon3,
  • Jae Hwan Nam4,
  • Young Ran Ju5 and
  • Young Bong Kim1Email author
Virology Journal20096:115

DOI: 10.1186/1743-422X-6-115

Received: 20 April 2009

Accepted: 30 July 2009

Published: 30 July 2009

Abstract

As noted in other flaviviruses, the envelope (E) protein of Japanese encephalitis virus (JEV) interacts with a cellular receptor and mediates membrane fusion to allow viral entry into target cells, thus eliciting neutralizing antibody response. The formation of the flavivirus prM/E complex is followed by the cleavage of precursor membrane (prM) and membrane (M) protein by a cellular signalase. To test the effect of prM in JEV biology, we constucted JEV-MuLV pseudotyped viruses that express the prM/E protein or E only. The infectivity and titers of JEV pseudotyped viruses were examined in several cell lines. We also analyzed the neutralizing capacities with anti-JEV sera from JEV-immunized mice. Even though prM is crucial for multiple stages of JEV biology, the JEV-pseudotyped viruses produced with prM/E or with E only showed similar infectivity and titers in several cell lines and similar neutralizing sensitivity. These results showed that JEV-MuLV pseudotyped viruses did not require prM for production of infectious pseudotyped viruses.

Findings

Japanese encephalitis virus (JEV) is a serious mosquito-borne flavivirus that causes pandemic infectious disease of major public health importance in Asia. JEV is a member of the genus Flavivirus in the family Flaviviridae, which includes yellow fever virus, Dengue virus, West Nile virus, and St. Louis encephalitis virus [1, 2].

The JEV single-stranded RNA genome (≈ 11 kb) encodes three structural proteins – capsid (C), premembrane (prM) or membrane (M), and envelope (E) protein – and seven nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) proteins [35].

The assembly of JEV in the endoplasmic reticulum is followed by modification of the two envelope proteins E and prM and virion export through the secretory pathway. PrM (≈ 26 kDa) is a precursor of the membrane-anchored and it cleaved a soluble Pr peptide and virion associated M protein (≈ 8 kDa) by trans-Golgi resident furin or related enzyme [6], resulting in two different forms of virion: the intracellular E- and prM-containing form, and the extracellular E- and M-containing form [3, 7].

The E protein plays a major role in virus assembly, adhesion, receptor binding and membrane fusion, hemagglutination inhibition (HI), and induction of neutralizing antibodies (Nabs) [810]. Therefore, the E protein is the principal target of neutralization by specific antibodies against JEV infection [4, 11]. E proteins of JEV expressed in different viral vector systems such as vaccinia virus, sindbis virus, and baculovirus have elicited high levels of neutralizing antibodies against JEV infection and have been tested as second generation JEV vaccines in mice [7, 1214]. From these reports, it is unknown whether prM cleavage affects infectivity, E protein expression, or induction of neutralizing activity. A major function of prM was studied by blocking prM cleavage or by mutation of the conserved glycosylation motif of JEV prM [15]. Even though the direct role of prM during the viral replication was not elucidated [6], it has a crucial function in multiple stages of JEV biology.

We generated pseudotyped viruses containing the prM/E or E protein of the current JEV vaccine strains Nakayama-NIH (NK) and Beijing-1 (BJ). The DNA fragments encoding the E and prM/E regions were amplified by polymerase chain reaction (PCR) from the cDNA of the NK strain and BJ strain kindly supplied from the Department of Vaccine, KFDA, Korea. PCRs were performed using one of the two forward primers: for prM/E amplification, 5'-AATGAGAATTC GACCATGTGGCTCGCAAGCTTGGC-3'; and for E amplification, 5'-GGTCGCGAATTC TGCAGGTTCAACTGTCTGGGAGTG-3'. The reverse primer for both amplifications was 5'-ACCAATGTGCATGCTTAGCTCGAGAATTC CATTG-3'. Each primer had an EcoR I restriction site. To generate pHCMV-prM/E and pHCMV-E, the PCR products of prM/E and E were digested with EcoR I and subsequently cloned into pHCMV-G [16] digested with EcoR I (Figure 1).
https://static-content.springer.com/image/art%3A10.1186%2F1743-422X-6-115/MediaObjects/12985_2009_Article_629_Fig1_HTML.jpg
Figure 1

Construction of JEV pHCMV-prM/E and pHCMV-E. Four plasmids were produced: pHCMV-prM/E (NK or BJ) and pHCMV-E (NK or BJ).

Pseudotyped viruses encoding prM/E or E of JEV NK and BJ strain were produced as previously described [17]. Briefly, TELCeB6 cells, a MuLV packaging cell line [18], were transfected with pHCMV-E or pHCMV-prM/E by a calcium phosphate method. After overnight incubation, the culture medium was replaced, and the cells were incubated for two additional days. The supernatants containing pseudotyped viruses were harvested by low speed centrifugation (1,500 × g, 5 min) to remove cell debris.

Figure 2 shows the expression of the E proteins from each pseudotyped JEV constructs by western blot analysis using anti-JEV (Nakayama) sera. The envelope genes of the NK and BK strains were expressed well in cell culture supernatants and lysates. Similar amounts of E proteins were expressed in NK and BJ transfected cells.
https://static-content.springer.com/image/art%3A10.1186%2F1743-422X-6-115/MediaObjects/12985_2009_Article_629_Fig2_HTML.jpg
Figure 2

Expression of JEV envelope (E) protein. Cell lysate and culture media of JEV-pseudotyped viruses were subjected to SDS-PAGE. JEV-E proteins were detected by western blotting using sera from mice immunized with JEV (Nakayama-NIH strain). The bands show the JEV-E protein (53 kDa) in cell lysates and culture supernatants. Non-transfected TELCeB6 cells were used as a negative control.

The JEV-pseudotyped viruses expressing prM-E and E were properly processed and released into the culture media with similar levels of expression. However prM-E polyprotein bands were not detected despite many attempts. To check the expression of the prM/Env gene during pseudotyped virus formation, we performed reverse transcription (RT)-PCR. Figure 3 shows the amplified JEV prM/Env (2062 bp), Env (1501 bp) transcripts in transfected TELCeB6 cells. We assumed that the cleavage of the prM protein is too rapid to detect with prM/E polyprotein and our sera from JEV-immunized mice did not contain the prM antibodies.
https://static-content.springer.com/image/art%3A10.1186%2F1743-422X-6-115/MediaObjects/12985_2009_Article_629_Fig3_HTML.jpg
Figure 3

Expression of JEV prM and Env genes in TELCeB6 cells. TELCeB6 cells were transfected with pHCMV-prM/E and pHCMV-E of each of NK and BJ strains. RT-PCR products of the indicated size were amplified from total RNA samples extracted from TELCeB6 cells. The products correspond to 2 Kb of prM (amplified by prM/E primer) and 1.5 Kb of Env (amplified by E primer). The molecular marker (Kb) is shown on the left.

To test the effect of prM on pseudotyped viral infectivity and viral titer, infection tests with the pseudotyped viruses were carried out in in 96-well plates with Vero, PK15, CRFK, NIH3T3, HeLa, 293T, BHK-21, MDCK, and HOS cells. Four kinds of pseudotyped JEVs were added to the host cells and incubated at 37°C in a 5% CO2 incubator for 36 hours. All infections were done in triplicate. After X-gal staining, JEV pseudotyped virus-infected cells appeared blue. This resulted from integration of the MuLV pseudovirus genome encoding β-galactosidase. These cells were counted as an infectious unit. All JEV pseudotyped viruses could infect PK15, CRFK, NIH3T3, HeLa, 293T, BHK-21, Vero, and MDCK cells, but not HOS cells (Table 1).
Table 1

Infectivity and titer of JEV pseudotyped viruses in host cells

Infectious units/ml (IFU/ml)

 

Host cell

JEV pseudotyed virus

Vero

BHK-21

HeLa

CRFK

PK15

293T

MDBK

HOS

NK prM/E

4.09 *104

7.46 *103

4.08 *103

9.74 *104

1.33 *103

1.14 *102

2.08 *102

0

NK E

4.25 *104

7.58 *103

4.12 *103

1.20 *105

1.09 *103

1.32 *102

2.11 *102

0

BJ prM/E

4.12 *104

7.76 *103

4.35 *103

1.02 *105

1.82 *103

2.04 *102

2.08 *102

0

BJ E

4.83*104

7.91 *103

4.29 *103

1.36*105

2.90 *103

2.05 *102

2.23 *102

0

The titers of pseudotyped viruses were comparable to the infectivity of JEV in each host cell line. JEV pseudotyped virus with E or prM/E (both NK and BJ strain) could efficiently infect several cell lines, with typical titers between 1.14 × 102 and 1.36 × 105 infectious units (IFU)/mL. From Table 1, viruses pseudotyped with prM/E exhibited infectivity similar to those pseudotyped with E only. This showed that the infectivity and titer of JEV pseudotyped virus is not affected by prM deletion.

Neutralizing sensitivity was tested with JEV-immunized immune sera, which was supplied by the Catholic University of Korea, to check the effect of prM on pseudotyped JEV antigens. As previously described [17], neutralization assays were carried out with Vero cells in triplicate. Approximately 100 IFU/mL of pseudotyped viruses were incubated with 10-fold diluted sera from mice immunized with JEV for 1 h at 37°C, and the mixture was subsequently added to Vero cells. After 2 days of incubation, virus infection was monitored by X-gal staining as described above. The neutralizing sensitivity was expressed as virus reduction by neutralizing antibodies.

Figure 4 shows the reduction of pseudotyped JEVs by neutralization with homologous and heterologous sera. A high neutralization was observed with 1:10 diluted serum. In contrast, no neutralizing activity was detected in the normal mouse serum (reduction was less than 30%). The neutralization by homologous sera was more complete than that by heterologous sera. However, there was no significant difference between pseudotyped JEV prM/Env and Env.
https://static-content.springer.com/image/art%3A10.1186%2F1743-422X-6-115/MediaObjects/12985_2009_Article_629_Fig4_HTML.jpg
Figure 4

Neutralizing assay with JEV pseudotyped viruses. Four different JEV-pseudotyped viruses (NK-prM/E, dark grey; NK-E, black; BJ-prM/E, white; BJ-E, light grey) were incubated with sera from mice immunized with JEV-NK strain or JEV-BJ strain. Neutralizations were determined with 1:10 diluted serum.

In summary, we generated pseudotyped JEVs that express prM/E or E proteins from two JEV vaccine strains NK and BJ. All four JEV pseudotyped viruses efficiently infected several cell lines and were neutralized by sera from JEV-immunized mice. The main purpose of generating JEV pseudotyped virus was to devise a safe and rapid assay system to assess neutralizing antibodies by avoiding the use of infectious, replication-competent JEVs in a Biosafety Level 3 laboratory. The titer of the four JEV pseudotyped viruses was greater than 104 IFU/ml. This confirmed the possibility of mass-producing viruses to conduct neutralization assays with Vero and CRFK cells. Even though a crucial function of prM in assembly and maturation of flaviviruses has been reported, the two types of JEV-MuLV pseudotyped virus that respectively express the E or prM/E proteins were found to have no significant difference in the level of transcription and the extent of protein expression, infectivity, titer, and neutralization sensitivity.

Declarations

Acknowledgements

This work was supported by a grant (20070501034009) from BioGreen 21 Program, Rural Development Administration and a Agricultural R&D Promotion Center, Ministry for Agriculture, Forestry and Fisheries, (608001-5), and a grant [K09040] from the Korea Institute of Oriental Medicine, Republic of Korea.

Authors’ Affiliations

(1)
Department of Animal Biotechnology, College of Animal Bioscience and Technology, Konkuk University
(2)
Virus Vaccines Division, Korea Food & Drug Administration
(3)
Center for Herbal Medicine Improvement Research, Korea Institute of Oriental Medicine
(4)
Department of Biotechnology, The Catholic University of Korea
(5)
Division of Arboviruses, Center for Immunology and Pathology, National Institute of Health, Korea Centers for Disease Control and Prevention

References

  1. Kuno G, Chang GJ, Tsuchiya KR, Karabatsos N, Cropp CB: Phylogeny of the genus Flavivirus. J Virol 1998, 72: 73-83.PubMed CentralPubMedGoogle Scholar
  2. Venugopal K, Gould EA: Towards a new generation of flavivirus vaccines. Vaccine 1994, 12: 966-975. 10.1016/0264-410X(94)90329-8View ArticlePubMedGoogle Scholar
  3. Yasuda A, Kimura-Kuroda J, Ogimoto M, Miyamoto M, Sata T, Sato T, Takamura C, Kurata T, Kojima A, Yasui K: Induction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express PreM and E glycoproteins of Japanese encephalitis virus. J Virol 1990, 64: 2788-2795.PubMed CentralPubMedGoogle Scholar
  4. Kaur R, Vrati S: Development of a recombinant vaccine against Japanese encephalitis. J Neurovirol 2003, 9: 421-431. 10.1080/713831600View ArticlePubMedGoogle Scholar
  5. Wu SC, Lian WC, Hsu LC, Liau MY: Japanese encephalitis virus antigenic variants with characteristic differences in neutralization resistance and mouse virulence. Virus Res 1997, 51: 173-181. 10.1016/S0168-1702(97)00098-1View ArticlePubMedGoogle Scholar
  6. Keelapang P, Sriburi R, Supasa S, Panyadee N, Songjaeng A, Jairungsri A, Puttikhunt C, Kasinrerk W, Malasit P, Sittisombut N: Alterations of pr-M cleavage and virus export in pr-M junction chimeric dengue viruses. J Virol 2004, 78: 2367-2381. 10.1128/JVI.78.5.2367-2381.2004PubMed CentralView ArticlePubMedGoogle Scholar
  7. Konishi E, Fujii A, Mason PW: Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles. J Virol 2001, 75: 2204-2212. 10.1128/JVI.75.5.2204-2212.2001PubMed CentralView ArticlePubMedGoogle Scholar
  8. Chen HW, Pan CH, Liau MY, Jou R, Tsai CJ, Wu HJ, Lin YL, Tao MH: Screening of protective antigens of Japanese encephalitis virus by DNA immunization: a comparative study with conventional viral vaccines. J Virol 1999, 73: 10137-10145.PubMed CentralPubMedGoogle Scholar
  9. Kurane I: Immune responses to Japanese encephalitis virus. Curr Top Microbiol Immunol 2002, 267: 91-103.PubMedGoogle Scholar
  10. Mason PW, Dalrymple JM, Gentry MK, McCown JM, Hoke CH, Burke DS, Fournier MJ, Mason TL: Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein. J Gen Virol 1989,70(Pt 8):2037-2049. 10.1099/0022-1317-70-8-2037View ArticlePubMedGoogle Scholar
  11. Kojima A, Yasuda A, Asanuma H, Ishikawa T, Takamizawa A, Yasui K, Kurata T: Stable high-producer cell clone expressing virus-like particles of the Japanese encephalitis virus e protein for a second-generation subunit vaccine. J Virol 2003, 77: 8745-8755. 10.1128/JVI.77.16.8745-8755.2003PubMed CentralView ArticlePubMedGoogle Scholar
  12. Wu HH, Chen CT, Lin YL, Lee ST: Sub-fragments of the envelope gene are highly protective against the Japanese encephalitis virus lethal infection in DNA priming – protein boosting immunization strategies. Vaccine 2004, 22: 793-800.View ArticlePubMedGoogle Scholar
  13. Zhao Z, Wakita T, Yasui K: Inoculation of plasmids encoding Japanese encephalitis virus PrM-E proteins with colloidal gold elicits a protective immune response in BALB/c mice. J Virol 2003, 77: 4248-4260. 10.1128/JVI.77.7.4248-4260.2003PubMed CentralView ArticlePubMedGoogle Scholar
  14. Konishi E, Pincus S, Paoletti E, Shope RE, Burrage T, Mason PW: Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology 1992, 188: 714-720. 10.1016/0042-6822(92)90526-UView ArticlePubMedGoogle Scholar
  15. Kim JM, Yun SI, Song BH, Hahn YS, Lee CH, Oh HW, Lee YM: A single N-linked glycosylation site in the Japanese encephalitis virus prM protein is critical for cell type-specific prM protein biogenesis, virus particle release, and pathogenicity in mice. J Virol 2008, 82: 7846-7862. 10.1128/JVI.00789-08PubMed CentralView ArticlePubMedGoogle Scholar
  16. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK: Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993, 90: 8033-8037. 10.1073/pnas.90.17.8033PubMed CentralView ArticlePubMedGoogle Scholar
  17. Kim YB, Lee MK, Han DP, Cho MW: Development of a safe and rapid neutralization assay using murine leukemia virus pseudotyped with HIV type 1 envelope glycoprotein lacking the cytoplasmic domain. AIDS Res Hum Retroviruses 2001, 17: 1715-1724. 10.1089/08892220152741414View ArticlePubMedGoogle Scholar
  18. Schnierle BS, Stitz J, Bosch V, Nocken F, Merget-Millitzer H, Engelstadter M, Kurth R, Groner B, Cichutek K: Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc Natl Acad Sci USA 1997, 94: 8640-8645. 10.1073/pnas.94.16.8640PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Lee et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement